Saniona AB: Saniona publishes the Annual Report fo
Post# of 301275
PRESS RELEASE
May 2, 2017
Saniona, a leading biotech company in the field of ion channels, today announces that the English version of the Annual report for 2016 is now available on the company's website www.saniona.com.
In addition, Saniona updates the financial calendar, which now is as follows:
Interim Report Q1 May 11, 2017 Annual General Meeting May 23, 2017 Interim Report Q2 August 23, 2017 Interim Report Q3 November 15, 2017 Year-End Report 2017 February 21, 2018
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com
This information is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on May 2, 2017.
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A and Luc Therapeutics, Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 5,000 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com .
Attachments: Attachments:
(0)
(0)